These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 37490229)

  • 1. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
    DuVall AS; Wesevich A; Larson RA
    Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
    Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
    Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
    Huang YH; Wan CL; Dai HP; Xue SL
    Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development.
    Thomas X
    Expert Opin Investig Drugs; 2023 Jan; 32(1):37-52. PubMed ID: 36541671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
    Lu XT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
    Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD
    Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Frey NV; Luger SM
    Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
    Zhang X; Yang J; Li J; Qiu L; Zhang J; Lu Y; Zhao YL; Jin D; Li J; Lu P
    Am J Hematol; 2023 Dec; 98(12):1898-1908. PubMed ID: 37740926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Adult Acute Lymphoblastic Leukemia.
    Richard-Carpentier G; Kantarjian H; Jabbour E
    Curr Hematol Malig Rep; 2019 Apr; 14(2):106-118. PubMed ID: 30879177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
    Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
    J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.
    Cramer SD; Aplan PD; Durum SK
    Blood; 2016 Jul; 128(4):473-8. PubMed ID: 27268088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
    Jeha S
    Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
    Si Lim SJ; Ford JB; Hermiston ML
    Blood; 2023 Jun; 141(25):3019-3030. PubMed ID: 37018730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
    Advani A
    Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
    Paolino J; Dimitrov B; Apsel Winger B; Sandoval-Perez A; Rangarajan AV; Ocasio-Martinez N; Tsai HK; Li Y; Robichaud AL; Khalid D; Hatton C; Gillani R; Polonen P; Dilig A; Gotti G; Kavanagh J; Adhav AA; Gow S; Tsai J; Li Y; Ebert BL; Van Allen EM; Bledsoe J; Kim AS; Tasian SK; Cooper SL; Cooper TM; Hijiya N; Sulis ML; Shukla NN; Magee JA; Mullighan CG; Burke MJ; Luskin MR; Mar BG; Jacobson MP; Harris MH; Stegmaier K; Place AE; Pikman Y
    Clin Cancer Res; 2023 Nov; 29(22):4613-4626. PubMed ID: 37725576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
    Summers RJ; Teachey DT
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):718-725. PubMed ID: 35941070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
    Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
    Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.